<DOC>
	<DOCNO>NCT02795650</DOCNO>
	<brief_summary>This multicenter , open label , randomise phase II clinical trial patient metastatic adenocarcinoma pancreas . Patients randomise experimental arm undergone tumoral biopsy start first line treatment administer personalised therapy second third line .</brief_summary>
	<brief_title>Personalised Therapy Patients With Metastatic Adenocarcinoma Pancreas Determined Genetic Testing Avatar Model Generation</brief_title>
	<detailed_description>This multicenter , open label , randomise phase II clinical trial patient metastatic adenocarcinoma pancreas . Patients metastatic disease randomise experimental control arm . Those experimental arm undergone tumoral biopsy order perform exome sequencing , bioinformatic report , avatar mouse model drug test . This information allow expertise panel elaborate treatment recommendation second third line treatment . Patients control arm receive treatment per investigator´s judge . The main objective trial determine whether personalised treatment achieve improve 1-year overall survival .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adenocarcinoma pancreas . ECOG performance status 0 1 Age ≥ 18 year old . Willingness male female subject , surgically sterile postmenopausal , use reliable method birth control ( oral contraceptive , intrauterine device , barrier method use spermicide ) duration study . One sit metastasis one susceptible biopsy . Measurable evaluable disease No prior treatment radiotherapy , surgery , chemotherapy investigational treatment metastatic disease three cycle first line chemotherapy . Palliative radiotherapy bone metastasis allow . Adjuvant neoadjuvant radiotherapy chemotherapy allow finished 6 month ago patient remain toxicity . Bone marrow function follow , 14 day prior randomisation : ANC &gt; 1,500 cells/mm3 Platelets &gt; 100,000 cells/mm3 Hemoglobin ≥9 g/dl Adequate liver , renal bone marrow function . AST ( SGOT ) , ALT ( SGPT ) ≤ 2.5 × ULN ≤ 5 x ULN liver metastasis . Bilirubin ≤ 1,5 x ULN Albumin total ≥ 0,75 ULN Creatinine ≤ 1,5 x ULN Ability sign inform consent Patients allow randomise . Brain metastasis , unless previously treat stable 3 month least ( defined oedema , need steroid stable disease two CT scan separate minimum 4 week ) . Locally advanced disease . Malignancies pancreatic cancer diagnose within 5 year prior randomization , except adequately treat carcinoma situ basal squamous cell skin cancer . Bacterial , viral fungal active infection require systemic treatment . Any contraindication tumor biopsy . Past present HIV hepatitis B C infection . Severe medical problem affect organ psychiatric illness could interfere safety patient trial . Pregnancy breastfeed woman . Patient need inform agree undergo tumoral biopsy experimental arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Pancreas</keyword>
</DOC>